Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study

NCT03316872 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03316872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03316872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Terminated
Start date
February 15, 2018
Completion date
February 15, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma